Long QT Syndrome

• 

  Subject Areas on Research

  • A CACNA1C variant associated with reduced voltage-dependent inactivation, increased CaV1.2 channel window current, and arrhythmogenesis. 
  • A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. 
  • A case of severe ischemia-induced QT prolongation. 
  • A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients. 
  • A young patient with exercise-induced polymorphic ventricular tachycardia. 
  • AHA scientific statement: practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association Scientific Statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized electrocardiology and the American Association of Critical-Care Nurses. 
  • Abnormal cardiac Na(+) channel properties and QT heart rate adaptation in neonatal ankyrin(B) knockout mice. 
  • Amino acid-level signal-to-noise analysis of incidentally identified variants in genes associated with long QT syndrome during pediatric whole exome sequencing reflects background genetic noise. 
  • An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. 
  • Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. 
  • Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. 
  • Antipsychotic medications and sudden cardiac death. 
  • Ca2+/calmodulin-dependent protein kinase II (CaMKII) regulates cardiac sodium channel NaV1.5 gating by multiple phosphorylation sites. 
  • Calcium Channel Mutations in Cardiac Arrhythmia Syndromes. 
  • Calcium influx through L-type CaV1.2 Ca2+ channels regulates mandibular development. 
  • Cardiac causes of sudden death: virtual panel discussion of posed questions. 
  • Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. 
  • Clinical Trial in a Dish: Personalized Stem Cell-Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT-Prolonging Drugs. 
  • Comparative analysis of media effects on human induced pluripotent stem cell-derived cardiomyocytes in proarrhythmia risk assessment. 
  • Comparison of automated interval measurements by widely used algorithms in digital electrocardiographs. 
  • Congenital long QT syndrome: considerations for primary care physicians. 
  • Critical reviews in basic electrophysiology: realizing the synergy between the basic and clinical sciences. 
  • Detection of QT prolongation using a novel electrocardiographic analysis algorithm applying intelligent automation: prospective blinded evaluation using the Cardiac Safety Research Consortium electrocardiographic database. 
  • Dialysate calcium concentration and the risk of sudden cardiac arrest in hemodialysis patients. 
  • Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. 
  • ERRgamma regulates cardiac, gastric, and renal potassium homeostasis. 
  • Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. 
  • Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study. 
  • Electroencephalography laboratory diagnosis of prolonged QT interval. 
  • Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol. 
  • Frequency of high-risk use of QT-prolonging medications. 
  • Genetics of cardiac repolarization. 
  • Hereditary long Q-T syndrome presenting as epilepsy: electroencephalography laboratory diagnosis. 
  • High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. 
  • Images in clinical medicine. Internal ventricular defibrillation. 
  • Impact of gene patents and licensing practices on access to genetic testing for long QT syndrome. 
  • Implantable cardioverter defibrillator in high-risk long QT syndrome patients. 
  • Improving the assessment of heart toxicity for all new drugs through translational regulatory science. 
  • Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. 
  • KCNQ1 assembly and function is blocked by long-QT syndrome mutations that disrupt interaction with calmodulin. 
  • Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. 
  • Management of Ventricular Arrhythmias and Sudden Cardiac Death Risk Associated With Cardiac Channelopathies. 
  • Measures of cardiac repolarization and body position in infants. 
  • Medications that prolong the QT interval. 
  • Molecular biology of sodium channels and their role in cardiac arrhythmias. 
  • Mouse model of Timothy syndrome recapitulates triad of autistic traits. 
  • Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): design and clinical protocol. 
  • Multiple different missense mutations in the pore region of HERG in patients with long QT syndrome. 
  • Multiple effects of KPQ deletion mutation on gating of human cardiac Na+channels expressed in mammalian cells. 
  • Novel insights into beta-blocker therapy for long QT syndromes. 
  • Novel long QT syndrome-associated missense mutation, L762F, in CACNA1C-encoded L-type calcium channel imparts a slower inactivation tau and increased sustained and window current. 
  • Novel missense mutation in the cyclic nucleotide-binding domain of HERG causes long QT syndrome. 
  • On power and sample size calculation for QT studies with recording replicates at given time point. 
  • Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. 
  • Preoperative diagnosis of long QT syndrome in an infant with tetralogy of Fallot. 
  • Pro: The Food and Drug Administration Black box warning on droperidol is not justified. 
  • QT as a safety biomarker in drug development. 
  • QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. 
  • Race and gender variation in the QT interval and its association with mortality in patients with coronary artery disease: results from the Duke Databank for Cardiovascular Disease (DDCD). 
  • Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. 
  • Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. 
  • Risks and challenges of implantable cardioverter-defibrillators in young adults. 
  • Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome. 
  • S-Nitrosylation of cardiac ion channels. 
  • Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. 
  • Seizures, syncope, or breath-holding presenting to the pediatric neurologist--when is the etiology a life-threatening arrhythmia? 
  • Sequential ionic and conformational signaling by calcium channels drives neuronal gene expression. 
  • Statistical analysis methods for QT/QTc prolongation. 
  • Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables. 
  • Targeted disruption of the Kvlqt1 gene causes deafness and gastric hyperplasia in mice. 
  • The Cardiac Safety Research Consortium ECG database. 
  • The Cardiac Safety Research Consortium electrocardiogram warehouse: thorough QT database specifications and principles of use for algorithm development and testing. 
  • The cardiac vulnerable period and reentrant arrhythmias: targets of anti- and proarrhythmic processes. 
  • Variability of action potential duration in pharmacologically induced long QT syndrome type 1. 
  • What clinicians should know about the QT interval. 
  • beta-Adrenergic action on wild-type and KPQ mutant human cardiac Na+ channels: shift in gating but no change in Ca2+:Na+ selectivity. 
  • α1-Syntrophin Variant Identified in Drug-Induced Long QT Syndrome Increases Late Sodium Current. 
• 

  Keywords of People

  • Bennett, Vann, George Barth Geller Distinguished Professor of Molecular Biology, Duke Cancer Institute
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Landstrom, Andrew Paul, Assistant Professor of Pediatrics, Cell Biology
  • Middleton, John Paul, Associate Professor of Medicine, Medicine, Nephrology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Starmer, Charles Franklin, Professor Emeritus of Computer Science, Computer Science